This week, we will discuss the CONFIRM trial. It was supposed to confirm the role of terlipressin in reversing hepatorenal syndrome…unfortunately it hit the nephrology nihilism wall.
Terlipressin: The visual abstract
Gorgeous work by Alicja Rosołowska & Pooja Sanghi for this week’s NephJC on terlipressin and hepatorenal syndrome
The Dual Dustat Visual abstracts
UPDATE:
On April 6, 2021 Fibrogen announced that the analysis of the cardiovascular outcomes was adjusted after the data was unblinded. When the data was reanalyzed without this adjustment roxadustat is less impactful. Importantly for this NephJC discussion, the previously impressive MACE and MACE+ advantage for incident dialysis is no longer found. Roxadustat remains non-inferior in all outcomes, though the confidence intervals have widened.
The Incident dialysis visual abstract has been updated to reflect this change.
At their first attempt, the NSMC interns Alicja Rosolowska and Keia Sanderson have created beautiful visual abstract